Technology
Upcoming Earnings
Health

BeyondSpring

$17.60
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.12 (-0.69%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell BeyondSpring and other stocks, options, ETFs, and crypto commission-free!

About

BeyondSpring Inc. Ordinary Shares, also called BeyondSpring, is a clinical stage company, which engages in the development of cancer therapies. Read More It focuses on non-small cell lung cancer, neutropenia prevention, and plinabulin and nivolumab. The company was founded by Lan Huang and Lin Qing Jia in 2013 and is headquartered in New York, NY.

Employees
38
Headquarters
New York, New York
Founded
2013
Market Cap
410.71M
Price-Earnings Ratio
β€”
Dividend Yield
0.00
Average Volume
7.31K
High Today
$17.77
Low Today
$17.53
Open Price
$17.53
Volume
209.00
52 Week High
$33.30
52 Week Low
$16.15

Collections

Technology
Upcoming Earnings
Health
Pharmaceutical
Cancer Prevention
Medical
2017 IPO
US

News

Markets Insider14h

BeyondSpring Advancing Patient Targeting Strategies for Lead Asset Plinabulin

NEW YORK, March 25, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, announced today that the Company will present novel data relevant to predictive biomarkers for patient selection for its lead asset, Plinabulin, at the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta, Georgia. The results from this non-clinical study will be highlighted in a poster presentation titled, β€œPre...

6
Markets InsiderMar 20

BeyondSpring to Present Clinical Trial Data on Lead Asset, Plinabulin, at 2019 St. Gallen International Breast Cancer Conference

NEW YORK, March 20, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Company will present clinical data on its lead asset, Plinabulin, during a poster presentation at the 2019 St. Gallen International Breast Cancer Conference, being held on March 20 through 23 in Vienna, Austria. Abstract P017 Title: β€œA Randomized Clinical Trial of the Combination of Plinabulin (Plin) + Pegfil...

16
Seeking AlphaFeb 26

BeyondSpring's Plinabulin shows positive action in mid-stage breast cancer study

New data from a Phase 2 clinical trial, Study 106, evaluating BeyondSpring's (BYSI +0.1% ) lead drug Plinabulin compared to Amgen's (AMGN +0.1% ) Neulasta (pegfilgrastim) in reducing the duration of severe neutropenia (abnormally low levels of a type of white blood cell) in certain breast cancer patients showed a positive effect.

42

Earnings

-$0.73
-$0.55
-$0.37
-$0.19
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.56 per share
Actual
Expected Mar 26, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.